Accéder au contenu
Merck
Toutes les photos(1)

Documents

Y0000703

Moxifloxacin hydrochloride

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

1-Cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydropyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C21H24FN3O4· HCl
Numéro CAS:
186826-86-8
Poids moléculaire :
437.89
Numéro Beilstein :
8377447
Numéro MDL:
MFCD00949117
Code UNSPSC :
41116107
ID de substance PubChem :
329831106
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

moxifloxacin

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

Cl.COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc4C(=O)C(=CN(C5CC5)c14)C(O)=O

InChI

1S/C21H24FN3O4.ClH/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24;/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28);1H/t11-,16+;/m0./s1

Clé InChI

IDIIJJHBXUESQI-DFIJPDEKSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Moxifloxacin hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

1448606

Moxifloxacin hydrochloride, United States Pharmacopeia (USP) Reference Standard

1448617

Moxifloxacin Related Compound A, United States Pharmacopeia (USP) Reference Standard

1448640

Moxifloxacin Related Compound D, United States Pharmacopeia (USP) Reference Standard

1448639

Moxifloxacin Related Compound C, United States Pharmacopeia (USP) Reference Standard

1448628

Moxifloxacin Related Compound B, United States Pharmacopeia (USP) Reference Standard

1448655

Moxifloxacin Related Compound E, United States Pharmacopeia (USP) Reference Standard

1448672

Moxifloxacin Related Compound G, United States Pharmacopeia (USP) Reference Standard

1448661

Moxifloxacin Related Compound F, United States Pharmacopeia (USP) Reference Standard

Y0002099

Moxifloxacin for peak identification A, European Pharmacopoeia (EP) Reference Standard

Y0002078

Moxifloxacin for system suitability, European Pharmacopoeia (EP) Reference Standard

Y0002081

Moxifloxacin for peak identification B, European Pharmacopoeia (EP) Reference Standard

Pictogrammes

Exclamation mark
GHS07

Mention d'avertissement

Warning

Mentions de danger

H302,H319,H412

Classification des risques

Acute Tox. 4 Oral - Aquatic Chronic 3 - Eye Irrit. 2

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Choose from one of the most recent versions:

Certificats d'analyse (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Rohit Shetty et al.
BioMed research international, 2014, 340509-340509 (2014-10-11)
To report the profile of microbial keratitis occurring after corneal collagen cross-linking (CXL) in keratoconus patients. A retrospective analysis of 2350 patients (1715 conventional CXL, 310 transepithelial CXL, and 325 accelerated CXL) over 7 years (from January 2007 to January
Cemile Banu Cosar et al.
European journal of ophthalmology, 24(3), 325-329 (2013-09-24)
To investigate refractive and visual outcomes and complications of the Supracor procedure to treat presbyopia. A total of 123 eyes from 68 presbyopic patients with hyperopia were enrolled in this prospective, nonrandomized, clinical trial. The Supracor procedure was performed using
Lingmin He et al.
JAMA ophthalmology, 133(1), 51-59 (2014-10-17)
Wavefront-guided (WFG) and wavefront-optimized (WFO) platforms for refractive surgery are designed for improved visual outcomes. It is unclear which treatment profile is superior for patients undergoing photorefractive keratectomy (PRK). To compare the safety, efficacy, predictability, stability, and higher-order aberrations in
Sumeet Khanduja et al.
Journal of glaucoma, 24(4), 267-271 (2013-01-23)
To evaluate the change in anterior chamber angle parameters after scleral buckling surgery using anterior segment optical coherence tomography (ASOCT). Fifty-five phakic eyes of 55 subjects undergoing scleral buckling with the placement of an encircling band for primary rhegmatogenous retinal
Lingmin He et al.
American journal of ophthalmology, 157(6), 1170-1178 (2014-02-25)
To compare the clinical outcomes of wavefront-guided and wavefront-optimized laser in situ keratomileusis (LASIK). Prospective, randomized, fellow-eye-controlled study. The setting was a single academic institution. The study population included 110 eyes of 55 patients with myopia with and without astigmatism.
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique